A recent study by University of Eastern Finland found that prediabetes has increased significantly in Finnish children living with overweight or obesity, rising from 11% to 50% over two decades. The study suggests a potential link between maternal overweight and the rise in child prediabetes prevalence.
A large cohort study found that statins significantly reduce the risk of death and major cardiovascular events in adults with type 2 diabetes. The findings challenge long-standing uncertainty about whether patients at low risk benefit from preventive statin therapy, suggesting that the drugs may have broader protective value.
A comprehensive review highlights the urgent need to transform unsustainable food systems, which drive both obesity and environmental harms. The authors recommend subsidies for healthy foods, taxes on unhealthy products, and restrictions on aggressive marketing to address these twin crises.
A major review in Frontiers in Science highlights how unsustainable food systems contribute to both health and climate crises. Experts examine evidence-based strategies to tackle industrial food systems promoting overconsumption and environmental pressures.
Researchers found that the healthy Nordic diet was more effective in reducing blood glucose levels and improving body weight, inflammation, and lipid profile compared to other diets. The study also showed that participants lost weight despite being allowed to eat as much as they wanted from recommended foods.
A recent study found that home-delivered groceries can significantly improve blood sugar control among adults with type 2 diabetes who experience food insecurity. The program provided culturally relevant, medically tailored groceries and education materials, leading to a clinically meaningful reduction in hemoglobin A1c levels.
SourceElsevier·JournalJournal of Nutrition Education and Behavior·TypeExperimental study·DateDec 10, 2025
Using GLP-1 receptor agonists may lower the risk of vertebral compression fractures and related surgical interventions in people with type 2 diabetes. The study suggests that these medications have a bone-protective effect, offering benefits for patients.
A systematic review and meta-analysis found that GLP-1 receptor agonists probably have little or no effect on the risk of thyroid, pancreatic, breast, or kidney cancer in patients with type 2 diabetes or overweight/obesity. However, longer-term studies are needed to clarify potential risks or benefits for other obesity-related cancers.
Researchers from The University of Osaka found that blood sugar migration to saliva in individuals with type 2 diabetes causes an imbalance in the oral microbiome, leading to cavity development. Improved glycemic control reduces this imbalance and the risk of tooth decay.
A study published in Environmental Endocrinology found that teens with higher blood levels of PFAS before bariatric surgery had smaller improvements in blood sugar over five years. This could lead to the metabolic benefits of the surgery fading within a decade.
A large study found that people with type 1 and type 2 diabetes have a higher risk of sudden cardiac death, particularly in younger adults. The research also showed that sudden cardiac death contributes to shorter life expectancy for those with diabetes.
The UCF Health Mobile Health Clinic provides free high-quality healthcare services to underserved communities, serving as a real-world classroom for medical and nursing students. The clinic aims to reduce preventable conditions and improve long-term health through comprehensive screenings, chronic disease monitoring, and education.
A research team at Max-Planck-Gesellschaft found that pregnant mice exposed to fatty food smells developed more pronounced obesity and insulin resistance in their offspring. The brains of the offspring showed similarities to those of obese adult mice, suggesting a potential link between maternal diet and child health.
A nationwide observational study from SWEDEHEART reveals that patients with type 1 diabetes have a significantly higher risk of stent complications compared to those without diabetes. The study emphasizes the need for adapted treatment and follow-up strategies for this patient group.
Researchers at University of Cologne identify p35-mediated CDK5 hyperactivity as a central mechanism limiting nerve regeneration in diabetes. Targeted interventions using peptides restore nerve fiber growth, leading to significant motor and sensory improvements.
Researchers used MRI 3D mapping to analyze changes in gluteus maximus shape over time and its association with type 2 diabetes. The study found that men showed muscle shrinkage, while women showed enlarged muscle, highlighting sex-specific differences in response to insulin tolerance.
The report emphasizes the importance of pairing research with policy partners and investing in mentorship and career advancement of Latino scientists and students. It also calls for implementing evidence-based practices, using telemedicine and AI equitably, and designing trauma-informed interventions that fit Latino family life.
Researchers identified 251 genetic variants that significantly affect circulating protein levels in Greenlanders, showing stronger genetic control over certain proteins in the Inuit population. The study uncovered 70 previously unreported associations and found links between Arctic-adapted genes and disease development.
A study comparing GLP-1 RAs found that all three drugs are relatively safe options for patients with type 2 diabetes, with minimal differences in kidney and cardiovascular risks. Liraglutide had a lower risk of all-cause mortality compared to dulaglutide.
Researchers found that prasugrel may offer an advantage over ticagrelor for individuals with Type 1 or Type 2 diabetes and complex coronary disease. This is because the two medications are not interchangeable, and treatment with prasugrel may provide better benefits in preventing blood clots and adverse cardiac events.
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
A comprehensive analysis of 70,000 participants across 10 trials found that SGLT2 inhibitors reduced the risk of chronic kidney disease (CKD) progression by 38% and slowed eGFR decline by 51%. The treatment was beneficial for all levels of kidney function and albuminuria levels, particularly in reducing hospitalizations.
The study suggests that SGLT2 inhibitors can benefit patients with varying levels of kidney function and albuminuria. Routine use of these medications may lead to improved kidney outcomes across different patient groups.
A new poll finds that 65% of Americans would try a low-fat, plant-based diet to prevent type 2 diabetes or improve blood sugar control. The poll also reveals that most adults are unaware of the benefits of high fruit and vegetable intake for reducing diabetes risk.
Researchers explore the link between senescent cells and metabolic diseases, highlighting potential treatments known as senotherapeutics. Senolytics, senomorphics, and senosensitizers are interventions aimed at eliminating or suppressing senescent cells to mitigate metabolic disease.
A study found that following steps to improve cardiovascular health can reduce the risk of mild cognitive impairment and dementia among people with Type 2 diabetes. Maintaining optimal cardiovascular health may protect brain health even for individuals with a high genetic risk for dementia.
A preliminary study found that low-dose aspirin use was associated with a lower risk of major cardiovascular events, including heart attacks and strokes, among adults with Type 2 diabetes. The analysis of 11,500 individuals over 10 years showed that consistent aspirin use led to significant reductions in cardiovascular event rates.
A new observational study found that semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes. The medications were assessed in a large database of adults with T2D, who underwent treatment with these GLP-1 RA medications between 2019 and 2024.
A new study found that combining GLP-1 receptor agonist medications with healthy lifestyle habits significantly reduces the risk of major adverse cardiovascular events, including heart attacks and strokes. The research suggests that adopting multiple healthy behaviors can lower cardiovascular risk even further.
This cross-sectional study found an increase in GLP-1RA prescriptions, with Tirzepatide and semaglutide growing the fastest due to their superior glycemic, weight loss, and guideline-emphasized cardiorenal benefits. However, coverage for obesity is limited, especially among off-label semaglutide use in non-T2D patients.
Frequent continuous glucose monitoring (CGM) use is associated with better glycemic control in people with type 2 diabetes. Clinicians should encourage CGM use and monitor its impact on therapy.
Type 2 diabetes has become a global epidemic with unequal burden, driven by ageing, dietary shifts, sedentary behaviour, and early-life exposures. The true cost of diabetes includes significant healthcare and economic burdens, but prevention remains the weakest link.
Researchers found that magnetic mitohormesis, a non-invasive treatment, can activate metabolic pathways triggered by exercise, improving glucose control without physical strain. Patients with excess belly fat experienced significant improvements in blood glucose control and HbA1c levels.
SourceSingHealth·JournalJournal of Clinical Medicine·TypeRandomized controlled/clinical trial·DateOct 30, 2025
Three new Cochrane reviews found GLP-1 drugs result in clinically meaningful weight loss, but evidence on longer-term outcomes and side effects is limited. The wider use of these drugs should consider social and commercial determinants to avoid deepening existing health inequities.
SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateOct 29, 2025
Researchers develop a compound that reduces cell death, inflammation, and organ damage in diabetes. The drug candidate, RAGE406R, prevents the interaction between two proteins that enable heart and kidney injury, and accelerates wound closure.
A new study published in PLOS One found that nearly one-third of adults with type 2 diabetes in India achieved remission through a comprehensive mobile-based program combining diet, exercise, stress management, and medical support. The program showed significant improvements in weight, body mass index, glycated hemoglobin levels, fasti...
A recent study published in Pediatric Research highlights the impact of neighborhood environments on childhood type 2 diabetes risk. The research found associations between library presence, neighborhood walkability, and caregiver health, suggesting that social and environmental factors play a significant role in T2D development.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
Researchers found SGLT-2 inhibitors reduce autoimmune rheumatic diseases by 11% compared to sulfonylureas. The study analyzed over 2 million adults with type 2 diabetes and suggests these drugs may contribute to a lower risk of autoimmune diseases.
A comparative effectiveness study found that liraglutide, semaglutide, and dulaglutide have similar risks for kidney and cardiovascular outcomes in veterans with type 2 diabetes. Head-to-head trials are needed to confirm these findings.
A study of 5,794 adults found that different types of depression are associated with varying levels of risk for cardiometabolic diseases. Those with atypical/energy-related symptoms were more likely to develop Type-2 diabetes, while those with melancholic symptoms were at higher risk for cardiovascular disease.
Researchers at City of Hope have identified a gene called SMOC1 that converts insulin-producing cells into those that increase blood sugar, shedding light on the progression of type 2 diabetes. This discovery offers new therapeutic targets and potential treatments for T2D.
A recent study found that primary care providers in Ohio perceive and treat opioid use disorder (OUD) differently from other chronic conditions like type 2 diabetes. Despite recognizing OUD as a chronic brain disease, providers were less likely to offer treatment themselves.
A new study found that AI tool accurately captures details in just three minutes from a body scan, highlighting the potential of using AI to repurpose data from routine scans. Visceral adipose tissue volume and fat deposits in muscle are strongly associated with diabetes and cardiovascular disease risk.
A study conducted at the University of Eastern Finland found that group-based and online lifestyle counselling can help middle-aged and older men adopt healthier dietary habits, leading to a lower risk of type 2 diabetes. Those with a high genetic risk for type 2 diabetes saw the most significant benefits from fibre-rich diets.
A new study published in Diabetes, Obesity and Metabolism found that weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes. The study analyzed data from over 180,000 people and found a significant reduction in cancer incidence ...
A 'light-touch' EHR referral strategy successfully connected patients with prediabetes to community-based DPPs, with 122 out of 577 referred patients enrolling. The strategy was used by 30% of targeted clinicians and accounted for over half of all referrals.
The SURPASS-PEDS trial shows that tirzepatide significantly improves HbA1c levels, BMI, and fasting glucose in children aged 10-17 years with type 2 diabetes. The study demonstrates sustained improvements over a year-long period, making it a potential safe and efficacious treatment option for youth-onset type 2 diabetes.
A UK Biobank study suggests that people with type 2 diabetes progress to additional chronic conditions at a faster rate than those without the condition. The study found that individuals with T2D experience a 60% higher risk of new disease diagnosis compared to those without T2D.
A new study published in Pharmaceutics found that semaglutide provides powerful protection against diabetic retinopathy, a condition that can lead to sight loss. The study suggests that GLP-1 receptor agonists enhance retinal cells' defences against damage in diabetes-like conditions.
A diet rich in wholegrains, fruits, and vegetables while limiting red meat and sugary drinks may help prevent type 2 diabetes and reduce greenhouse gas emissions. Higher adherence to this planetary health diet was associated with a 32% lower incidence of type 2 diabetes and 18% lower greenhouse emissions.
A large community-based study has found that individuals with type 2 diabetes are at a doubled risk of developing sepsis, particularly among younger adults and men. The study identified several modifiable risk factors, including smoking, high blood sugar, and complications of diabetes.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
Two large-scale clinical trials found that a higher dose of semaglutide significantly improves weight loss and related health outcomes in adults with obesity. The study revealed an average weight loss of nearly 19% in those receiving the higher dose, compared to 10% with the standard dose or placebo.
SourceThe Lancet·JournalThe Lancet Diabetes & Endocrinology·TypeRandomized controlled/clinical trial·DateSep 14, 2025
Women with type 2 diabetes taking oral hormone replacement therapy are at a higher risk of developing pulmonary embolism and heart disease. Transdermal HRT, on the other hand, appears safer, reducing cardiovascular risk by up to 25%.
A new study analyzing real-world data from over 4 million adults found that cannabis users face almost four times the risk of developing type 2 diabetes within five years compared to non-users. The study suggests that long-term metabolic effects of cannabis use may be linked to insulin resistance and unhealthy dietary behaviors.
A new European study of over 45,000 individuals aged 50-plus found a significant association between diabetes and depression, with individuals having diabetes increasing their risk of developing severe depressive symptoms by 48%, regardless of country. Conversely, those with high depressive symptoms had a 15% higher odds of developing ...
Research from Sweden, Norway, and Finland shows smoking significantly raises type 2 diabetes risk across all subtypes, with severe insulin-resistant diabetes (SIRD) being the most affected. Heavy smokers face greater risks, especially those with genetic predispositions.
Researchers found genetic peptides called alpha-defensins that shape gut bacteria, producing healthier microbiomes and reducing insulin resistance. This discovery suggests personalized treatments can be tailored to individual genes, offering new hope for addressing chronic diseases like obesity and diabetes.
A 14-year study highlights the importance of diagnosing and treating obstructive sleep apnea in people with type 2 diabetes. The research suggests that continuous positive airway pressure (CPAP) treatment can reduce mortality risk by up to 26%.